## EQR: Equity Residential - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_20 1.5% below STRENGTH zone (4.0-10.0%); PEG 8.15 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.34)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. How Investors May Respond To Equity Residential (EQR) Raising Guidance and Rebalancing Its Portfolio**
- Source: Simply Wall Street | 20251201T122732 | Neutral | Relevance: 99%
- Equity Residential (EQR) recently reported strong Q3 2025 normalized FFO per share, meeting expectations and leading the company to raise its annual guidance. Concurrently, EQR strategically acquired a 375-unit property and divested two others, demonstrating a proactive approach to portfolio optimization. The article discusses how these actions and EQR's long-term outlook, including projected revenue and earnings, may influence investor sentiment.

**2. CPT (Camden Property Trust) Change In Payables And Accrued Expense : $-0 Mil (TTM As of Sep. 2025)**
- Source: GuruFocus | 20251130T150559 | Neutral | Relevance: 62%
- This article defines and provides historical data for Camden Property Trust's (CPT) "Change In Payables And Accrued Expense." It details the quarterly and annual changes in this metric, explaining its relevance as the increase or decrease in Accounts Payable & Accrued Expense between periods. The data covers periods up to September 2025, offering insights into the company's financial operations.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | Barclays | $77 | $80 | -4% |
| 2025-11-24 | Mizuho | $65 | $66 | -2% |
| 2025-11-17 | Truist Securiti | $70 | $75 | -7% |
| 2025-11-13 | Morgan Stanley | $74 | $75 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | Barclays | main | Overweight |
| 2025-11-24 | Mizuho | main | Neutral |
| 2025-11-17 | Truist Securiti | main | Buy |
| 2025-11-13 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 15.1% (+2.3%)
- Blackrock Inc.: 10.2% (+1.1%)
- State Street Corpora: 6.6% (+2.8%)
- Price (T.Rowe) Assoc: 5.2% (-4.5%)
- Apg Asset Management: 3.0% (-0.7%)

### Key Risks

1. Valuation stretched: PEG 8.2x requires aggressive growth execution.
2. Long-term trend broken: trading 7.5% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 8.15 signals overvaluation risk, limited margin of safety. Forward P/E 42.9x stretched relative to 6% growth. Quality metrics strong (margin 38%). Analyst sentiment negative (4 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.9B |
| Beta | 0.76 |
| 52W Range | $58.38 - $75.86 |
| Short Interest | 2.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 8.15 |
| Forward P/E | 42.9 |
| Current P/E | 45.6 |
| YoY Growth | 6.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.7% to 1.5% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. Below SMA200 (0.93x), long-term trend not supportive. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.46% (CS: 68) | Neutral |
| RSI_14 | 55.4 | Neutral |
| MACD Histogram | 0.40 | Bullish |
| vs SMA20 | 1.025x | Above |
| vs SMA50 | 0.997x | Below |
| vs SMA200 | 0.925x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $61.44
- **Stop Loss:** $59.34 (3.4% risk)
- **Target:** $63.54 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $14,622.72
- **Portfolio %:** 14.62%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $0.38)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.37 | -11.5% |
| 2025Q2 | $0.30 | $0.34 | +12.6% |
| 2025Q1 | $0.27 | $0.26 | -4.9% |
| 2024Q4 | $0.40 | $0.26 | -35.9% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*